Rein Therapeutics (RNTX) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Telomir Pharmaceuticals (TELO) has outperformed Rein Therapeutics (RNTX) over the past year, losing 71.6% versus a loss of 77.2%. Rein Therapeutics is the larger company by market cap ($29.1 million vs $26.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNTX | TELO |
|---|---|---|
| Share price | $0.3369 | $0.364 |
| Market cap | $29.06M | $26.82M |
| 1-day change | -8.38% | -17.24% |
| YTD return | -70.96% | -72.63% |
| 1-year return | -77.24% | -71.56% |
| 5-year return | -97.47% | — |
| EPS (TTM) | $-1.51 | $-0.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-49.87M | $-10.41M |
| 52-week high | $2.10 | $1.58 |
| 52-week low | $0.284 | $0.353 |
| Distance from 52-week high | -83.96% | -76.96% |
| Analyst consensus | none | none |
| Avg. price target upside | +1680.94% | +998.90% |
| Average volume | 586.68K | 126.14K |
| Shares outstanding | 86.27M | 73.68M |
| Employees | 10 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
RNTX vs TELO FAQ
Which is bigger, Rein Therapeutics or Telomir Pharmaceuticals?
Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $26.82M for Telomir Pharmaceuticals (TELO).
Which stock has performed better over the past year, RNTX or TELO?
TELO returned -71.56% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are Rein Therapeutics and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.